EFSA has halved its tolerable upper intake level for vitamin B6 in supplements to 12mg/day, a limit more than eight times lower than the cap set by the US and the World Health Organization. Hylobates Consulting's Luca Bucchini expects that this lower UL will push the EU to set a maximum permitted level for vitamin B6 in supplements which is "massively lower" than currently applied by some member states.
Manufacturers of dietary supplements containing vitamin B6 sold in the EU are likely facing product reformulations after the European Food Safety Authority recommended halving the tolerable upper intake level (UL) for adults.
In a draft scientific opinion, EFSA’s panel on Nutrition, Novel Foods and Food Allergens reduces the UL for vitamin...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
